BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11384090)

  • 1. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
    Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
    Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
    Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
    Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
    Samonigg H; Wilders-Truschnig M; Kuss I; Plot R; Stöger H; Schmid M; Bauernhofer T; Tiran A; Pieber T; Havelec L; Loibner H
    J Immunother; 1999 Nov; 22(6):481-8. PubMed ID: 10570746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
    Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
    Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
    Buckley DT; Robins AR; Durrant LG
    Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.
    Durrant LG; Buckley TJ; Denton GW; Hardcastle JD; Sewell HF; Robins RA
    Cancer Res; 1994 Sep; 54(18):4837-40. PubMed ID: 8069847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36.
    Austin EB; Robins RA; Durrant LG; Price MR; Baldwin RW
    Immunology; 1989 Aug; 67(4):525-30. PubMed ID: 2788611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
    Durrant LG; Buckley DJ; Robins RA; Spendlove I
    Int J Cancer; 2000 Jan; 85(1):87-92. PubMed ID: 10585589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.
    Maxwell-Armstrong C
    Ann R Coll Surg Engl; 2002 Sep; 84(5):314-8. PubMed ID: 12398121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.
    Maxwell-Armstrong CA; Durrant LG; Robins RA; Galvin AM; Scholefield JH; Hardcastle JD
    Gut; 1999 Oct; 45(4):593-8. PubMed ID: 10486371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current concepts in immunotherapy for the treatment of colorectal cancer.
    Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
    J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody.
    Denton GW; Durrant LG; Hardcastle JD; Austin EB; Sewell HF; Robins RA
    Int J Cancer; 1994 Apr; 57(1):10-4. PubMed ID: 8150527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
    Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
    Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
    Kapoor S; Pal S; Sahni P; Dattagupta S; Kanti Chattopadhyay T
    J Surg Res; 2005 Dec; 129(2):172-5. PubMed ID: 15882879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity.
    Durrant LG; Buckley DJ; Spendlove I; Robins RA
    Hybridoma; 1997 Feb; 16(1):23-6. PubMed ID: 9085124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-induced apoptosis: a novel clinical trial end point?
    Amin S; Robins RA; Maxwell-Armstrong CA; Scholefield JH; Durrant LG
    Cancer Res; 2000 Jun; 60(12):3132-6. PubMed ID: 10866299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.